Skip to main content
. Author manuscript; available in PMC: 2014 Nov 20.
Published in final edited form as: Exp Biol Med (Maywood). 2014 Jun 20;239(10):1340–1351. doi: 10.1177/1535370214539225

Figure 5. Analysis of C/EBPα and C/EBPβ protein levels following 0, 1, and 3 days exposure to indomethacin.

Figure 5

Protein levels of C/EBPα and C/EBPβ in UCMSCs treated with 60 µM indomethacin for 0 (black bar), 1 (gray bar), and 3 (white bar) days were analyzed via immunoblot analysis. The graph depicts densitometric quantitation of immunoblots probed for C/EBPα and C/EBPβ. Values are expressed as mean ± SE. Significance between groups was determined using a repeated measures two-way ANOVA, followed by Tukey’s test for multiple comparisons. For each time point, * represents a significant difference between MDI and both MDI-I and MDI-R, † represents a significant difference between MDI-I and MDI-R, ‡ represents a significant difference between MDI and MDI-R, and § represents a significant difference between MDI and MDI-I (P < 0.05).